Overtaking Intra and Inter Tumoral Heterogeneity In Von Hippel-Lindau Related Renal Cancer

Study acronym: ITHORinVHL
StatusCompleted
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed
    • Primary completion date changed from estimate of May 19, 2026 to Jun 18, 2025
    • Eligibility criteria expanded, about 5 words
    • Study description expanded, about 3 words
  2. Primary and study completion dates: Oct 31, 2025 to May 19, 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v4
  3. Primary and study completion dates: Aug 31, 2024 to Oct 31, 2025v3
  4. Study description shortened, about 1 wordv2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this study is to comprehensively map intra and inter tumor heterogeneity of ccRCC in VHL patients through the use of imaging, molecular biology and genomics techniques.
Trial Details
NCT Number NCT06195150
Lead Sponsor IRCCS San Raffaele
Conditions
(from sponsor)		 Clear Cell Renal Cell Carcinoma, VHL Syndrome
Related terms Carcinoma, Renal Cell, von Hippel-Lindau Disease
Enrollment 3 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov